1 citations
,
July 2025 in “Clinical and Experimental Dermatology” Deucravacitinib led to full hair regrowth in a severe alopecia areata patient.
1 citations
,
October 2025 in “Cureus” Ritlecitinib may cause severe musculoskeletal pain in some alopecia universalis patients.
April 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” Prostaglandin E2 helps prevent hair loss from radiotherapy by protecting hair growth cells and aiding self-repair.
May 2026 in “Drug Delivery and Translational Research” Nanocarriers with spironolactone and 2-deoxy-D-ribose may improve hair loss treatment by targeting hair follicles directly.
January 2004 in “Headache” Divalproex sodium significantly improved headaches in two-thirds of patients.
November 2025 in “Journal of Investigative Dermatology”
7 citations
,
September 2006 in “Clinical lymphoma & myeloma” Balancing treatment effectiveness with side effects is crucial for relapsed follicular non-Hodgkin's lymphoma, especially in older patients.
3 citations
,
May 2018 in “Reproductive Sciences” The drug BAY 1158061 is safe, well-tolerated, and shows potential for treating diseases related to prolactin.
294 citations
,
February 1994 in “PubMed” Valproic acid is an effective and safe first-choice treatment for many types of seizures.
August 2024 in “Case Reports in Ophthalmology” Older patients with new retinal lesions may have cancer, and local radiation might not stop it from spreading.
October 2023 in “The Open Dermatology Journal” Baricitinib is effective for severe alopecia areata with manageable side effects, mainly upper respiratory infections.
March 2026 in “Microchemical Journal” November 2025 in “Journal of Investigative Dermatology” May 2021 in “Zenodo (CERN European Organization for Nuclear Research)” 35 citations
,
March 2010 in “Journal of Dermatological Science” Ebastine may help regrow hair in alopecia areata patients.
2 citations
,
November 1990 in “International Journal of Dermatology” Albendazole can cause hair loss, and piroxicam can cause fixed drug eruption.
2 citations
,
July 2007 in “Cancer biology & therapy” Bexxar is highly effective as a first treatment for non-Hodgkin's lymphoma, with most patients alive and many in remission after eight years.
3 citations
,
November 2024 in “Clinical Research” Deuruxolitinib is FDA-approved for treating severe alopecia areata.
October 2023 in “Naunyn-Schmiedeberg's Archives of Pharmacology” Custom software found that common allergy drugs might have new uses for various conditions and could improve survival in some cancers.
21 citations
,
March 2015 in “Journal of The American Academy of Dermatology” Vemurafenib therapy can cause hair loss, but clobetasol propionate foam can help regrow hair.
20 citations
,
December 2011 in “Journal of inherited metabolic disease” Valproic acid treatment increases a specific acid in urine by blocking an enzyme, possibly causing skin rash and hair loss.
7 citations
,
March 2002 in “AIDS” Indinavir, especially with vitamin A, may cause bone changes, but switching to nelfinavir can reduce these effects.
June 2020 in “Journal of clinical and investigative dermatology” Nourkrin® Woman with Marilex® improves hair growth, appearance, and confidence in women with hair loss.
March 2021 in “Arrow - TU Dublin (Technological University Dublin)” The folate-cyclodextrin conjugate targets cancer cells more precisely, potentially reducing chemotherapy side effects.
37 citations
,
October 2006 in “Archives of Biochemistry and Biophysics” A unique gene mutation causes vitamin D-resistant rickets without causing hair loss.
196 citations
,
September 2016 in “JCI insight” Ruxolitinib effectively regrows hair in most patients with severe hair loss.
4 citations
,
August 2022 in “The Scientific World Journal” Merremia peltata leaf extract, particularly the bufotalinin compound, shows potential for treating hair loss.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Baricitinib is effective and safe for treating severe alopecia areata for up to 5 years.